{
    "nctId": "NCT04403529",
    "briefTitle": "Evaluating the Clinical Value of Traditional Chinese Medicine in the Adjuvant Therapy of Triple-negative Breast Cancer",
    "officialTitle": "Evaluating the Clinical Value of Traditional Chinese Medicine in the Adjuvant Therapy of Triple-negative Breast Cancer",
    "overallStatus": "UNKNOWN",
    "conditions": "Triple Negative Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 200,
    "primaryOutcomeMeasure": "Disease free survival",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Women aged 18-70 years old;\n* Pathologically confirmed stage I-III breast cancer after early breast cancer surgery, and is confirmed by histopathology to be triple negative breast cancer (estrogen receptor (ER)-negative/ progesterone receptor (PR)-negative/ human epidermal growth factor receptor 2 (HER2)-negative). HER2-negative is defined as a negative in situ hybridization test or an immunohistochemistry (IHC) status of 0, 1+ or 2+. If IHC is 2+, a negative in situ hybridization test is required by local laboratory testing;\n* Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; life expectancy is \u2265 6 months;\n* Has adequate organ function meeting the following criteria: (1) adequate bone marrow function: hemoglobin \u2265 90 g/L (no blood transfusion within 14 days); absolute neutrophil count \u2265 1.5 x 109 /L; platelet count \u2265 100 \\* 109 /L; (2)adequate liver and kidney function: Alanine Aminotransferase (ALT) \u2264 3\u00d7upper limit of normal (ULN), Aspartate Aminotransferase (AST) \u2264 3\u00d7ULN, Total Bilirubin (TBIL)\u2264 1.5\u00d7ULN, serum creatinine \u2264 1\u00d7ULN\uff0cand with endogenous creatinine clearance rate of \\>50 ml/min (Cockcroft-Gault formula).\n* Participant has completed the last of their post surgical radiotherapy and chemotherapy within the last 6 months before date of enrollment, and no tumor recurrence or metastasis at the time of enrollment.\n* Participants voluntarily joined the study, has signed informed consent before any trial related activities are conducted, has good compliance and has agreed to follow-up.\n\nExclusion Criteria:\n\n* Has bilateral breast cancer;\n* Has previous history of additional malignancy, with the exception of adequately treated basal cell carcinoma and cervical carcinoma in situ.\n* Has metastatic (Stage 4) breast cancer;\n* Has any \\>T4 lesion (UICC1987) (with skin involvement, mass adhesion and fixation, and inflammatory breast cancer);\n* Is pregnant, is breast feeding women, or women of childbearing age who cannot practice effective contraceptives;\n* Patients participating in other drug related clinical trials at the same time;\n* Has severe organ dysfunction (cardiopulmonary liver and kidney) insufficiency, left ventricular ejection fraction (LVEF) \\< 50% (cardiac ultrasound); severe cardio cerebral vascular disease within the 6 months previous of randomization (such as unstable angina, chronic heart failure, uncontrolled hypertension with blood pressure\\>150/90mmgh, myocardial infarction, or cerebral blood vessel); diabetic patients with poor blood glucose control; patients with severe hypertension;\n* Has known allergy to study medication;\n* Has severe or uncontrolled infection;\n* Has a history of psychotropic substance abuse and were unable to abandon drug habits, or those with history of mental disorders;\n* The researchers judged patients to be unsuitable for the study.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}